According to a recent LinkedIn post from Moonfare, the firm is spotlighting several large private-market transactions, including a $1.1 billion funding round for UK AI lab Ineffable Intelligence and a €880 million secondary share sale by Lithuania-based Vinted. The post also notes that Thermo Fisher Scientific is divesting its microbiology unit for $1.08 billion, illustrating continued portfolio reshaping among large corporates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights these deals within its Weekly Wrap series, positioning Moonfare as an observer and curator of sizable activity across venture, secondary markets, and corporate carve-outs. For investors, the focus on AI capital formation, European tech liquidity events, and U.S. divestitures may indicate where Moonfare sees enduring deal flow and thematic opportunity in private markets.
The referenced blog and white papers, linked in the post, suggest Moonfare is investing in thought leadership to deepen engagement with sophisticated investors and allocators. While the post does not disclose any direct transaction involvement or financial impact for Moonfare, the emphasis on large-ticket deals in AI, fashion resale, and life sciences infrastructure could reinforce its brand as a gateway to institutional-style private market exposure.
The selection of transactions also underscores the breadth of private market activity across geographies and stages, from early-stage AI platforms to mature consumer platforms and specialized life sciences assets. If Moonfare continues to align its educational content with such sectors, it may strengthen its positioning with investors seeking diversified access to high-growth themes and secondary liquidity opportunities.